| NCT04430842 |
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S |
https://ClinicalTrials.gov/show/NCT04430842 |
Recruiting |
Quadriga Biosciences, Inc. |
2021-09-30 |
| NCT04042480 |
A Study of SGN-CD228A in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04042480 |
Recruiting |
Seattle Genetics, Inc. |
2023-01-31 |
| NCT03393858 |
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT03393858 |
Recruiting |
Capital Medical University |
2020-06-30 |
| NCT03319537 |
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma |
https://ClinicalTrials.gov/show/NCT03319537 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2020-10-31 |
| NCT03269227 |
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT03269227 |
Recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2020-07-31 |
| NCT03228537 |
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT03228537 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT03213301 |
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. |
https://ClinicalTrials.gov/show/NCT03213301 |
Active, not recruiting |
Swiss Group for Clinical Cancer Research |
2019-04-08 |
| NCT03212404 |
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT03212404 |
Recruiting |
Checkpoint Therapeutics, Inc. |
2021-07-31 |
| NCT03207347 |
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) |
https://ClinicalTrials.gov/show/NCT03207347 |
Recruiting |
University of Florida |
2021-12-31 |
| NCT03177668 |
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT03177668 |
Active, not recruiting |
Kissei Pharmaceutical Co., Ltd. |
2020-12-31 |
| NCT03126630 |
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT03126630 |
Recruiting |
National Cancer Institute (NCI) |
2022-02-02 |
| NCT03074513 |
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors |
https://ClinicalTrials.gov/show/NCT03074513 |
Recruiting |
M.D. Anderson Cancer Center |
2021-03-31 |
| NCT03068117 |
Malignant Mesothelioma - Can we Improve Quality of Life |
https://ClinicalTrials.gov/show/NCT03068117 |
Completed |
Portsmouth Hospitals NHS Trust |
2017-01-31 |
| NCT03063450 |
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma |
https://ClinicalTrials.gov/show/NCT03063450 |
Active, not recruiting |
University of Southampton |
2021-07-31 |
| NCT03054298 |
CAR T Cells in Mesothelin Expressing Cancers |
https://ClinicalTrials.gov/show/NCT03054298 |
Recruiting |
University of Pennsylvania |
2021-03-31 |
| NCT03048474 |
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT03048474 |
Active, not recruiting |
The Netherlands Cancer Institute |
2017-12-31 |
| NCT03023319 |
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03023319 |
Recruiting |
Augusta University |
2020-11-30 |
| NCT03007030 |
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT03007030 |
Recruiting |
M.D. Anderson Cancer Center |
2022-04-30 |
| NCT02991482 |
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02991482 |
Active, not recruiting |
European Thoracic Oncology Platform |
2020-12-31 |
| NCT02959463 |
Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02959463 |
Recruiting |
M.D. Anderson Cancer Center |
2020-05-31 |
| NCT02899299 |
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients |
https://ClinicalTrials.gov/show/NCT02899299 |
Active, not recruiting |
Bristol-Myers Squibb |
2021-04-15 |
| NCT02899195 |
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma |
https://ClinicalTrials.gov/show/NCT02899195 |
Active, not recruiting |
PrECOG, LLC. |
2020-02-16 |
| NCT02879669 |
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02879669 |
Active, not recruiting |
Targovax ASA |
2020-06-30 |
| NCT02875548 |
Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study |
https://ClinicalTrials.gov/show/NCT02875548 |
Recruiting |
Epizyme, Inc. |
2023-12-31 |
| NCT02863055 |
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT02863055 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2020-12-31 |
| NCT02860286 |
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT02860286 |
Completed |
Epizyme, Inc. |
2018-06-30 |
| NCT02859415 |
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases |
https://ClinicalTrials.gov/show/NCT02859415 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2028-08-03 |
| NCT02838745 |
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas |
https://ClinicalTrials.gov/show/NCT02838745 |
Recruiting |
Baylor College of Medicine |
2022-07-31 |
| NCT02798536 |
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT02798536 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2017-07-20 |
| NCT02758587 |
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) |
https://ClinicalTrials.gov/show/NCT02758587 |
Recruiting |
NHS Greater Glasgow and Clyde |
2019-05-31 |
| NCT02755675 |
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung |
https://ClinicalTrials.gov/show/NCT02755675 |
Recruiting |
Rigshospitalet, Denmark |
2023-04-30 |
| NCT02716272 |
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients |
https://ClinicalTrials.gov/show/NCT02716272 |
Active, not recruiting |
Intergroupe Francophone de Cancerologie Thoracique |
2018-02-28 |
| NCT02709512 |
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin |
https://ClinicalTrials.gov/show/NCT02709512 |
Recruiting |
Polaris Group |
2020-10-31 |
| NCT02707666 |
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02707666 |
Recruiting |
University of Chicago |
2022-12-20 |
| NCT02662504 |
Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02662504 |
Completed |
University Hospital, Lille |
2018-03-12 |
| NCT02649829 |
Autologous Dendritic Cell Vaccination in Mesothelioma |
https://ClinicalTrials.gov/show/NCT02649829 |
Recruiting |
University Hospital, Antwerp |
2020-10-31 |
| NCT02639091 |
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors |
https://ClinicalTrials.gov/show/NCT02639091 |
Completed |
Bayer |
2018-05-23 |
| NCT02637531 |
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 |
https://ClinicalTrials.gov/show/NCT02637531 |
Active, not recruiting |
Infinity Pharmaceuticals, Inc. |
2020-12-31 |
| NCT02611037 |
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02611037 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2020-12-31 |
| NCT02611024 |
Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors |
https://ClinicalTrials.gov/show/NCT02611024 |
Recruiting |
PharmaMar |
2020-11-30 |
| NCT02610140 |
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) |
https://ClinicalTrials.gov/show/NCT02610140 |
Completed |
Bayer |
2017-05-31 |
| NCT02599194 |
18F-FSPG PET/CT for Cancer Patients on Therapy |
https://ClinicalTrials.gov/show/NCT02599194 |
Completed |
Stanford University |
2016-12-14 |
| NCT02592551 |
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02592551 |
Active, not recruiting |
Baylor College of Medicine |
2020-09-01 |
| NCT02585362 |
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program |
https://ClinicalTrials.gov/show/NCT02585362 |
Completed |
Kantonsspital Winterthur KSW |
2018-10-31 |
| NCT04153565 |
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) |
https://ClinicalTrials.gov/show/NCT04153565 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2021-06-30 |
| NCT02568449 |
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent |
https://ClinicalTrials.gov/show/NCT02568449 |
Active, not recruiting |
Barbara Ann Karmanos Cancer Institute |
2019-06-01 |
| NCT04034238 |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors |
https://ClinicalTrials.gov/show/NCT04034238 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-12-01 |
| NCT03399552 |
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT03399552 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-12-31 |
| NCT02535312 |
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin |
https://ClinicalTrials.gov/show/NCT02535312 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02497508 |
Nivolumab in Patients With Recurrent Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT02497508 |
Completed |
The Netherlands Cancer Institute |
2017-07-31 |
| NCT02464904 |
Intrapleural Cryotherapy for Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02464904 |
Recruiting |
Mayo Clinic |
2020-12-31 |
| NCT02436733 |
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM |
https://ClinicalTrials.gov/show/NCT02436733 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2019-09-30 |
| NCT02414945 |
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients |
https://ClinicalTrials.gov/show/NCT02414945 |
Recruiting |
University Health Network, Toronto |
2025-06-30 |
| NCT02414269 |
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin |
https://ClinicalTrials.gov/show/NCT02414269 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-30 |
| NCT02397928 |
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) |
https://ClinicalTrials.gov/show/NCT02397928 |
Completed |
NovoCure Ltd. |
2018-04-30 |
| NCT02385812 |
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma |
https://ClinicalTrials.gov/show/NCT02385812 |
Recruiting |
University of Calgary |
2022-12-31 |
| NCT02369198 |
MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC |
https://ClinicalTrials.gov/show/NCT02369198 |
Completed |
Asbestos Diseases Research Foundation |
2017-01-04 |
| NCT02349958 |
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy |
https://ClinicalTrials.gov/show/NCT02349958 |
Recruiting |
Bay Area Gynecology Oncology |
2022-01-31 |
| NCT02349412 |
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers |
https://ClinicalTrials.gov/show/NCT02349412 |
Completed |
Alliance for Clinical Trials in Oncology |
2017-07-03 |
| NCT02347917 |
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02347917 |
Completed |
Sumitomo Dainippon Pharma Co., Ltd. |
2018-05-31 |
| NCT02293005 |
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT02293005 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-05-31 |
| NCT02194231 |
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) |
https://ClinicalTrials.gov/show/NCT02194231 |
Completed |
Mario Negri Institute for Pharmacological Research |
2019-12-12 |
| NCT02159716 |
CART-meso in Mesothelin Expressing Cancers |
https://ClinicalTrials.gov/show/NCT02159716 |
Completed |
University of Pennsylvania |
2015-11-30 |
| NCT02151448 |
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies |
https://ClinicalTrials.gov/show/NCT02151448 |
Completed |
University of Pittsburgh |
2019-02-18 |
| NCT02141347 |
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma |
https://ClinicalTrials.gov/show/NCT02141347 |
Completed |
AstraZeneca |
2017-01-27 |
| NCT02139904 |
Vinorelbine in Mesothelioma |
https://ClinicalTrials.gov/show/NCT02139904 |
Active, not recruiting |
Wales Cancer Trials Unit |
2019-10-31 |
| NCT02078700 |
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. |
https://ClinicalTrials.gov/show/NCT02078700 |
Completed |
Arcispedale Santa Maria Nuova-IRCCS |
2014-04-30 |
| NCT02071862 |
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors |
https://ClinicalTrials.gov/show/NCT02071862 |
Completed |
Calithera Biosciences, Inc |
2019-03-31 |
| NCT02040272 |
Mesothelioma and Radical Surgery 2 |
https://ClinicalTrials.gov/show/NCT02040272 |
Recruiting |
Royal Brompton & Harefield NHS Foundation Trust |
2020-09-30 |
| NCT02040142 |
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C |
https://ClinicalTrials.gov/show/NCT02040142 |
Recruiting |
Albert Einstein College of Medicine |
2021-11-30 |
| NCT03762018 |
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT03762018 |
Recruiting |
European Thoracic Oncology Platform |
2024-10-31 |
| NCT02408016 |
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma |
https://ClinicalTrials.gov/show/NCT02408016 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2020-06-30 |
| NCT01890980 |
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 |
https://ClinicalTrials.gov/show/NCT01890980 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-04-30 |
| NCT01843374 |
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT01843374 |
Active, not recruiting |
MedImmune LLC |
2016-01-24 |
| NCT02784171 |
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT02784171 |
Recruiting |
Canadian Cancer Trials Group |
2022-07-31 |
| NCT01722149 |
Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01722149 |
Completed |
University of Zurich |
2019-03-22 |
| NCT01721018 |
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. |
https://ClinicalTrials.gov/show/NCT01721018 |
Completed |
Virttu Biologics Limited |
2016-11-14 |
| NCT01675765 |
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01675765 |
Completed |
Aduro Biotech, Inc. |
2018-09-05 |
| NCT01644994 |
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01644994 |
Active, not recruiting |
University of Zurich |
2019-12-31 |
| NCT01592383 |
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma |
https://ClinicalTrials.gov/show/NCT01592383 |
Completed |
University of Chicago |
2017-02-28 |
| NCT01590160 |
Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01590160 |
Completed |
University College, London |
2019-11-05 |
| NCT01521325 |
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers |
https://ClinicalTrials.gov/show/NCT01521325 |
Completed |
Morphotek |
2013-03-31 |
| NCT04300244 |
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT04300244 |
Recruiting |
Oslo University Hospital |
2024-03-15 |
| NCT01503177 |
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01503177 |
Active, not recruiting |
Mayo Clinic |
2020-12-31 |
| NCT01486368 |
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01486368 |
Completed |
Canadian Cancer Trials Group |
2014-04-27 |
| NCT01401907 |
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies |
https://ClinicalTrials.gov/show/NCT01401907 |
Active, not recruiting |
Massachusetts General Hospital |
2016-04-30 |
| NCT01362790 |
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma |
https://ClinicalTrials.gov/show/NCT01362790 |
Completed |
National Institutes of Health Clinical Center (CC) |
2016-08-03 |
| NCT01358084 |
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM |
https://ClinicalTrials.gov/show/NCT01358084 |
Completed |
MolMed S.p.A. |
2018-12-05 |
| NCT01355965 |
Autologous Redirected RNA Meso-CIR T Cells |
https://ClinicalTrials.gov/show/NCT01355965 |
Completed |
University of Pennsylvania |
2015-07-31 |
| NCT04375267 |
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours |
https://ClinicalTrials.gov/show/NCT04375267 |
Recruiting |
Vastra Gotaland Region |
2022-06-30 |
| NCT04316689 |
First-in-human Study of S-588210 (S-488210+S-488211) |
https://ClinicalTrials.gov/show/NCT04316689 |
Recruiting |
Shionogi Inc. |
2020-10-31 |
| NCT04290325 |
HMPL-453 in Advanced Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT04290325 |
Recruiting |
Hutchison Medipharma Limited |
2022-11-30 |
| NCT04234113 |
Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT04234113 |
Recruiting |
Sotio a.s. |
2022-03-31 |
| NCT04213794 |
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study |
https://ClinicalTrials.gov/show/NCT04213794 |
Recruiting |
Mayo Clinic |
2025-01-30 |
| NCT04177953 |
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery |
https://ClinicalTrials.gov/show/NCT04177953 |
Recruiting |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2023-07-31 |
| NCT04173338 |
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT04173338 |
Recruiting |
Augusta University |
2020-11-30 |
| NCT04162015 |
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma |
https://ClinicalTrials.gov/show/NCT04162015 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2022-11-30 |
| NCT04115111 |
Diadem to Investigate the Activity and Safety of Durvalumab |
https://ClinicalTrials.gov/show/NCT04115111 |
Active, not recruiting |
Mario Negri Institute for Pharmacological Research |
2019-12-31 |
| NCT04088786 |
Phase I Trial HIPEC With Nal-irinotecan |
https://ClinicalTrials.gov/show/NCT04088786 |
Recruiting |
Stony Brook University |
2020-08-31 |
| NCT04056026 |
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma |
https://ClinicalTrials.gov/show/NCT04056026 |
Completed |
ProgenaBiome |
2018-12-18 |
| NCT04040231 |
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma |
https://ClinicalTrials.gov/show/NCT04040231 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2020-07-31 |
| NCT04028570 |
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection |
https://ClinicalTrials.gov/show/NCT04028570 |
Recruiting |
University Health Network, Toronto |
2024-04-30 |
| NCT04013334 |
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT04013334 |
Recruiting |
Momotaro-Gene Inc. |
2020-09-20 |
| NCT03983954 |
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03983954 |
Recruiting |
NeoTX Therapeutics Ltd. |
2021-11-01 |
| NCT03935893 |
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers |
https://ClinicalTrials.gov/show/NCT03935893 |
Recruiting |
University of Pittsburgh |
2029-06-01 |
| NCT03918252 |
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT03918252 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2025-06-30 |
| NCT03917043 |
APG-2449 in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03917043 |
Recruiting |
Ascentage Pharma Group Inc. |
2021-05-31 |
| NCT03907852 |
Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer |
https://ClinicalTrials.gov/show/NCT03907852 |
Recruiting |
TCR2 Therapeutics |
2021-06-30 |
| NCT03867578 |
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma |
https://ClinicalTrials.gov/show/NCT03867578 |
Recruiting |
University of Chicago |
2022-01-22 |
| NCT03852823 |
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours |
https://ClinicalTrials.gov/show/NCT03852823 |
Recruiting |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2022-09-30 |
| NCT03715933 |
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
https://ClinicalTrials.gov/show/NCT03715933 |
Recruiting |
Inhibrx, Inc. |
2020-07-31 |
| NCT03710876 |
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT03710876 |
Recruiting |
Trizell Ltd |
2023-11-30 |
| NCT03684486 |
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer |
https://ClinicalTrials.gov/show/NCT03684486 |
Recruiting |
University Hospital, Toulouse |
2020-02-01 |
| NCT03683680 |
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers |
https://ClinicalTrials.gov/show/NCT03683680 |
Recruiting |
Dana-Farber Cancer Institute |
2022-01-01 |
| NCT03656549 |
Dose Individualization of Pemetrexed - IMPROVE-I |
https://ClinicalTrials.gov/show/NCT03656549 |
Recruiting |
Radboud University |
2021-10-01 |
| NCT03655834 |
Dose Individualization of Pemetrexed - IMPROVE-III |
https://ClinicalTrials.gov/show/NCT03655834 |
Recruiting |
Radboud University |
2021-09-01 |
| NCT03655821 |
Dose Individualization of Pemetrexed - IMPROVE-II |
https://ClinicalTrials.gov/show/NCT03655821 |
Recruiting |
Radboud University |
2021-09-01 |
| NCT03654833 |
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT03654833 |
Recruiting |
University of Leicester |
2021-07-30 |
| NCT03644550 |
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT03644550 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-08-31 |
| NCT03638206 |
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies |
https://ClinicalTrials.gov/show/NCT03638206 |
Recruiting |
Shenzhen BinDeBio Ltd. |
2023-03-01 |
| NCT03610360 |
DENdritic Cell Immunotherapy for Mesothelioma |
https://ClinicalTrials.gov/show/NCT03610360 |
Recruiting |
Amphera BV |
2021-01-15 |
| NCT03560973 |
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM |
https://ClinicalTrials.gov/show/NCT03560973 |
Active, not recruiting |
Gruppo Oncologico Italiano di Ricerca Clinica |
2019-12-22 |
| NCT03556228 |
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT03556228 |
Recruiting |
VM Oncology, LLC |
2021-06-30 |
| NCT03546426 |
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies |
https://ClinicalTrials.gov/show/NCT03546426 |
Recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2021-01-31 |
| NCT03538028 |
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03538028 |
Recruiting |
Incyte Corporation |
2020-09-24 |
| NCT03517488 |
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03517488 |
Recruiting |
Xencor, Inc. |
2020-12-31 |
| NCT03507452 |
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin |
https://ClinicalTrials.gov/show/NCT03507452 |
Recruiting |
Bayer |
2023-12-20 |
| NCT03502746 |
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma |
https://ClinicalTrials.gov/show/NCT03502746 |
Recruiting |
Hoosier Cancer Research Network |
2020-06-30 |
| NCT03420963 |
Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors |
https://ClinicalTrials.gov/show/NCT03420963 |
Recruiting |
M.D. Anderson Cancer Center |
2022-12-01 |
| NCT03412357 |
MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. |
https://ClinicalTrials.gov/show/NCT03412357 |
Recruiting |
Papworth Hospital NHS Foundation Trust |
2019-12-01 |
| NCT01265433 |
WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy |
https://ClinicalTrials.gov/show/NCT01265433 |
Completed |
Sellas Life Sciences Group |
2017-07-25 |
| NCT01243632 |
Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment |
https://ClinicalTrials.gov/show/NCT01243632 |
Completed |
Institute of Oncology Ljubljana |
2010-06-30 |
| NCT01241682 |
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT01241682 |
Completed |
Erasmus Medical Center |
2011-10-31 |
| NCT01212367 |
Intrapleural Gene Transfer for Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01212367 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2015-05-31 |
| NCT01211275 |
Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT01211275 |
Completed |
The Netherlands Cancer Institute |
2012-11-13 |
| NCT01204203 |
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) |
https://ClinicalTrials.gov/show/NCT01204203 |
Completed |
University of Alabama at Birmingham |
2015-04-30 |
| NCT01160458 |
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy |
https://ClinicalTrials.gov/show/NCT01160458 |
Completed |
National Institutes of Health Clinical Center (CC) |
2016-08-13 |
| NCT01134146 |
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) |
https://ClinicalTrials.gov/show/NCT01134146 |
Completed |
M.D. Anderson Cancer Center |
2017-07-09 |
| NCT01126346 |
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) |
https://ClinicalTrials.gov/show/NCT01126346 |
Completed |
Wake Forest University Health Sciences |
2011-04-30 |
| NCT01119664 |
Combination Gene Transfer and Chemotherapy |
https://ClinicalTrials.gov/show/NCT01119664 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2013-10-14 |
| NCT01112293 |
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01112293 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2012-10-31 |
| NCT01098266 |
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed |
https://ClinicalTrials.gov/show/NCT01098266 |
Completed |
MolMed S.p.A. |
2014-04-29 |
| NCT01085630 |
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy |
https://ClinicalTrials.gov/show/NCT01085630 |
Active, not recruiting |
Alliance for Clinical Trials in Oncology |
2017-07-31 |
| NCT01064648 |
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01064648 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-06-01 |
| NCT01024946 |
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity |
https://ClinicalTrials.gov/show/NCT01024946 |
Completed |
Memorial Sloan Kettering Cancer Center |
2012-07-31 |
| NCT00996567 |
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. |
https://ClinicalTrials.gov/show/NCT00996567 |
Completed |
University Hospital, Ghent |
2015-09-30 |
| NCT00859469 |
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma |
https://ClinicalTrials.gov/show/NCT00859469 |
Completed |
Columbia University |
2009-03-31 |
| NCT00821860 |
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00821860 |
Completed |
Papworth Hospital NHS Foundation Trust |
2013-02-28 |
| NCT03608618 |
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma |
https://ClinicalTrials.gov/show/NCT03608618 |
Recruiting |
MaxCyte, Inc. |
2020-12-31 |
| NCT01997190 |
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion |
https://ClinicalTrials.gov/show/NCT01997190 |
Active, not recruiting |
Advantagene, Inc. |
2015-12-31 |
| NCT01776385 |
The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01776385 |
Completed |
Centre Hospitalier Universitaire de Nice |
2017-12-31 |
| NCT01766739 |
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma |
https://ClinicalTrials.gov/show/NCT01766739 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT01655225 |
A Study of LY3023414 in Participants With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT01655225 |
Active, not recruiting |
Eli Lilly and Company |
2019-04-04 |
| NCT01356251 |
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma |
https://ClinicalTrials.gov/show/NCT01356251 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-11-30 |
| NCT03531840 |
Olaparib in People With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT03531840 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2020-06-30 |
| NCT02903914 |
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT02903914 |
Recruiting |
Incyte Corporation |
2020-08-28 |
| NCT02834013 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
https://ClinicalTrials.gov/show/NCT02834013 |
Recruiting |
National Cancer Institute (NCI) |
2021-08-31 |
| NCT02399371 |
Pembrolizumab in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT02399371 |
Active, not recruiting |
University of Chicago |
2021-03-20 |
| NCT03652077 |
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03652077 |
Recruiting |
Incyte Corporation |
2021-01-31 |
| NCT00787410 |
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00787410 |
Completed |
AstraZeneca |
2008-04-30 |
| NCT00770120 |
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00770120 |
Completed |
Southwest Oncology Group |
2014-04-30 |
| NCT00738582 |
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00738582 |
Completed |
Morphotek |
2011-06-30 |
| NCT00715611 |
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00715611 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2020-07-31 |
| NCT00703638 |
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT00703638 |
Completed |
Masonic Cancer Center, University of Minnesota |
2010-09-30 |
| NCT00700336 |
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) |
https://ClinicalTrials.gov/show/NCT00700336 |
Completed |
CanBas Co. Ltd. |
2012-07-31 |
| NCT00652574 |
Dasatinib in Resectable Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00652574 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2019-03-31 |
| NCT00651456 |
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study |
https://ClinicalTrials.gov/show/NCT00651456 |
Completed |
Intergroupe Francophone de Cancerologie Thoracique |
2015-01-31 |
| NCT00634205 |
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00634205 |
Completed |
European Lung Cancer Working Party |
2009-03-31 |
| NCT00571298 |
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00571298 |
Completed |
Dana-Farber Cancer Institute |
2011-11-30 |
| NCT00541073 |
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00541073 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00535951 |
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00535951 |
Completed |
Novartis |
2009-01-31 |
| NCT00513877 |
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00513877 |
Completed |
Cancer Trials Ireland |
2009-12-31 |
| NCT00509041 |
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00509041 |
Completed |
Alliance for Clinical Trials in Oncology |
2010-02-28 |
| NCT00484276 |
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00484276 |
Completed |
MolMed S.p.A. |
2013-03-31 |
| NCT00469196 |
Tomotherapy Treatment for Mesothelioma |
https://ClinicalTrials.gov/show/NCT00469196 |
Completed |
AHS Cancer Control Alberta |
2015-05-31 |
| NCT00459862 |
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00459862 |
Completed |
National Cancer Institute (NCI) |
2009-04-30 |
| NCT00423254 |
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. |
https://ClinicalTrials.gov/show/NCT00423254 |
Completed |
Mannkind Corporation |
2009-09-30 |
| NCT00407459 |
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00407459 |
Completed |
Istituto Clinico Humanitas |
2010-11-30 |
| NCT00402766 |
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00402766 |
Completed |
M.D. Anderson Cancer Center |
2014-02-28 |
| NCT00398138 |
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma |
https://ClinicalTrials.gov/show/NCT00398138 |
Completed |
Memorial Sloan Kettering Cancer Center |
2009-06-30 |
| NCT00392444 |
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00392444 |
Completed |
National Cancer Institute (NCI) |
2012-01-31 |
| NCT00386815 |
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00386815 |
Completed |
Eli Lilly and Company |
NA |
| NCT00372840 |
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer |
https://ClinicalTrials.gov/show/NCT00372840 |
Completed |
Fox Chase Cancer Center |
2010-11-30 |
| NCT00365053 |
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00365053 |
Completed |
National Cancer Institute (NCI) |
2009-03-31 |
| NCT00334594 |
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00334594 |
Completed |
Swiss Group for Clinical Cancer Research |
2014-03-26 |
| NCT00325494 |
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer |
https://ClinicalTrials.gov/show/NCT00325494 |
Completed |
Morphotek |
2008-09-30 |
| NCT00316225 |
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen |
https://ClinicalTrials.gov/show/NCT00316225 |
Completed |
Eli Lilly and Company |
2009-03-31 |
| NCT00309946 |
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00309946 |
Completed |
National Cancer Institute (NCI) |
2010-09-30 |
| NCT00299962 |
Gene Therapy for Pleural Malignancies |
https://ClinicalTrials.gov/show/NCT00299962 |
Completed |
University of Pennsylvania |
2008-05-31 |
| NCT00295503 |
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00295503 |
Completed |
University of Texas Southwestern Medical Center |
2010-06-30 |
| NCT00280982 |
Dendritic Cell-based Immunotherapy in Mesothelioma |
https://ClinicalTrials.gov/show/NCT00280982 |
Completed |
Erasmus Medical Center |
2009-09-30 |
| NCT00272558 |
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00272558 |
Completed |
Rigshospitalet, Denmark |
2009-09-30 |
| NCT00251550 |
Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00251550 |
Completed |
Eli Lilly and Company |
NA |
| NCT00243074 |
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00243074 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00227630 |
Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00227630 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2007-08-31 |
| NCT00190762 |
A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma |
https://ClinicalTrials.gov/show/NCT00190762 |
Completed |
Eli Lilly and Company |
NA |
| NCT00165555 |
Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00165555 |
Completed |
Dana-Farber Cancer Institute |
2002-04-30 |
| NCT00165516 |
Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate |
https://ClinicalTrials.gov/show/NCT00165516 |
Completed |
Dana-Farber Cancer Institute |
2006-07-31 |
| NCT00137826 |
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma |
https://ClinicalTrials.gov/show/NCT00137826 |
Completed |
Dana-Farber Cancer Institute |
2007-03-31 |
| NCT00128102 |
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) |
https://ClinicalTrials.gov/show/NCT00128102 |
Completed |
Merck Sharp & Dohme Corp. |
2011-07-31 |
| NCT00107432 |
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. |
https://ClinicalTrials.gov/show/NCT00107432 |
Completed |
National Cancer Institute (NCI) |
2007-06-30 |
| NCT00101283 |
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00101283 |
Completed |
Eastern Cooperative Oncology Group |
2009-09-30 |
| NCT00003263 |
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00003263 |
Completed |
Fox Chase Cancer Center |
1999-12-31 |
| NCT00003974 |
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma |
https://ClinicalTrials.gov/show/NCT00003974 |
Completed |
Roswell Park Cancer Institute |
1998-06-30 |
| NCT00087698 |
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00087698 |
Completed |
Eli Lilly and Company |
2008-02-29 |
| NCT00003723 |
S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00003723 |
Completed |
Southwest Oncology Group |
2007-06-30 |
| NCT00005636 |
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00005636 |
Completed |
Memorial Sloan Kettering Cancer Center |
2000-11-30 |
| NCT00004254 |
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed |
https://ClinicalTrials.gov/show/NCT00004254 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2001-06-30 |
| NCT00004033 |
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00004033 |
Completed |
NYU Langone Health |
2001-05-31 |
| NCT00006014 |
SU5416 in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00006014 |
Completed |
National Cancer Institute (NCI) |
2007-02-28 |
| NCT00004183 |
Capecitabine in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00004183 |
Completed |
Alliance for Clinical Trials in Oncology |
2003-12-31 |
| NCT00075699 |
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT00075699 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00025207 |
Gefitinib in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00025207 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00066651 |
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT00066651 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00066404 |
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions |
https://ClinicalTrials.gov/show/NCT00066404 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2006-01-31 |
| NCT00062283 |
Alanosine in Treating Patients With Cancer |
https://ClinicalTrials.gov/show/NCT00062283 |
Completed |
National Cancer Institute (NCI) |
2005-12-31 |
| NCT00061477 |
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma |
https://ClinicalTrials.gov/show/NCT00061477 |
Completed |
Eli Lilly and Company |
NA |
| NCT00797719 |
Short Neoadjuvant Hemithoracic IMRT for MPM |
https://ClinicalTrials.gov/show/NCT00797719 |
Recruiting |
University Health Network, Toronto |
2020-07-31 |
| NCT00054002 |
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00054002 |
Completed |
Roswell Park Cancer Institute |
2006-06-30 |
| NCT00053885 |
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00053885 |
Completed |
Alliance for Clinical Trials in Oncology |
2005-07-31 |
| NCT00039182 |
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung |
https://ClinicalTrials.gov/show/NCT00039182 |
Completed |
National Cancer Institute (NCI) |
2007-06-30 |
| NCT00030745 |
Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung |
https://ClinicalTrials.gov/show/NCT00030745 |
Completed |
Swiss Group for Clinical Cancer Research |
2003-05-31 |
| NCT00030498 |
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00030498 |
Completed |
National Cancer Institute (NCI) |
2007-07-31 |
| NCT00027703 |
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00027703 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00024076 |
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer |
https://ClinicalTrials.gov/show/NCT00024076 |
Completed |
Jonsson Comprehensive Cancer Center |
2006-12-31 |
| NCT00020124 |
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs |
https://ClinicalTrials.gov/show/NCT00020124 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00019825 |
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura |
https://ClinicalTrials.gov/show/NCT00019825 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00017186 |
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00017186 |
Completed |
Alliance for Clinical Trials in Oncology |
2004-08-31 |
| NCT00006981 |
Immunotoxin Therapy in Treating Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00006981 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00006231 |
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00006231 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00004920 |
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura |
https://ClinicalTrials.gov/show/NCT00004920 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2003-01-31 |
| NCT00002608 |
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT00002608 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00002475 |
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00002475 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00037817 |
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies |
https://ClinicalTrials.gov/show/NCT00037817 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-10-08 |
| NCT00458913 |
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma |
https://ClinicalTrials.gov/show/NCT00458913 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2010-04-30 |
| NCT00004547 |
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy |
https://ClinicalTrials.gov/show/NCT00004547 |
Completed |
National Institutes of Health Clinical Center (CC) |
2009-08-31 |